Developing Drugs To Prevent Prostate Cancer Spread.
Funder
National Health and Medical Research Council
Funding Amount
$99,248.00
Summary
Current therapies for prostate cancer lose their efficacy as the cancer advances. Moreover, despite the spread of cancer being the major cause of prostate cancer mortality, there is no therapy available which selectively targets this process, thus new agents are needed. By using computer modelling to predict molecules that bind to the cell surface protein CD151 and testing these in biological assays, we aim to discover molecules that reduce cell migration of prostate cancer and that can be devel ....Current therapies for prostate cancer lose their efficacy as the cancer advances. Moreover, despite the spread of cancer being the major cause of prostate cancer mortality, there is no therapy available which selectively targets this process, thus new agents are needed. By using computer modelling to predict molecules that bind to the cell surface protein CD151 and testing these in biological assays, we aim to discover molecules that reduce cell migration of prostate cancer and that can be developed into anti-migration drugs.Read moreRead less
Actin filaments are part of a dynamic network of protein fibres inside each cell and play a role in cell shape, movement and division. Cancer cells hijack specific types of actin filaments to spread throughout the body. Our aim is to find out how protein machines assemble these filaments from actin and different binding proteins that give each filament its specific function. This insight will allow us to improve drugs that inhibit filaments associated with cancer.
Enhanced And Highly Specific Delivery Of Small Interfering RNA And Oligonucleotides As Therapeutics For Gene Silencing
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
This proposal aims to develop glyco-nanocarriers for the efficient and specific delivery of siRNA/oligonucleotides to treat liver diseases. Complex glycopolymer architectures developed here will protect desired genes from enzymatic degradation and will deliver the gene to the liver specifically for therapy, hence providing a solution towards nucleic acid therapy.
Design And Delivery Of Peptide-based Anti-cancer Grb7 Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$603,126.00
Summary
The Grb7 protein is overproduced in many types of cancer cells and plays a role in cancer cell growth and spread. The current proposal builds upon the discovery of a peptide-based Grb7 inhibitor that has anti-cancer activity. This proposal is to prepare more potent inhibitor molecules that can efficiently reach the target cancer cells. Such molecules will be used for the study of Grb7 and for the development of a new Grb7-based anti-cancer drug therapy.
Identification Of Cardiac Sarcoplasmic Reticulum Targets For Cardiotoxic Drugs
Funder
National Health and Medical Research Council
Funding Amount
$265,986.00
Summary
Anthracyclines are drugs which are used successfully in chemotherapy. Unfortunately, these drugs can lead to serious heart problems which sometimes result in death, and the mechanisms behind this remain elusive. Finding the specific targets of these drugs and how these drugs affect heart contraction may lead to designing drug cocktails which protect the heart from side effects.
The Putative Drug Metabolising Enzyme SULT4A1 Is A Sulfotransferase Inhibitor
Funder
National Health and Medical Research Council
Funding Amount
$467,851.00
Summary
The sulfotransferase SULT4A1 is a novel protein found predominantly in neurons but its function is unknown. This project will investigate the mechanisms that the body uses to regulate the levels of this protein and how it may interfere with other enzymes essential for metabolising hormones and neurotransmitters.
Understanding G Protein-Coupled Receptors (GPCRs): Accelerating Discovery From Concept To Clinic.
Funder
National Health and Medical Research Council
Funding Amount
$6,871,789.00
Summary
G Protein-Coupled Receptors (GPCRs) form the largest family of receptors (and thus drug targets) in living organisms. Currently, the major reason that new drugs fail to reach the clinic is lack of appropriate drug effect (approx. 30%). Thus, we need a better understanding of how GPCRs work and how this relates to disease. Our Program addresses this knowledge gap, using GPCR models that are relevant to treatment of metabolic, cardiovascular and central nervous system disease.
Taking The First Steps From Promise To Product: Exploration Of The Newly Discovered Interleukin 37 Receptor Complex And Its Signaling Pathways
Funder
National Health and Medical Research Council
Funding Amount
$694,623.00
Summary
Cytokines are messenger proteins used by most cells of the body. They function as master regulators of many biological processes and as such play an important role in a wide spectrum of diseases. Anti-inflammatory cytokines attenuate the potentially destructive force of other cytokines and the immune system as a whole, and are therefore coveted as drug targets. We discovered the formidable anti-inflammatory properties of IL-37 and will now explore how these activites can be utilised in clinical ....Cytokines are messenger proteins used by most cells of the body. They function as master regulators of many biological processes and as such play an important role in a wide spectrum of diseases. Anti-inflammatory cytokines attenuate the potentially destructive force of other cytokines and the immune system as a whole, and are therefore coveted as drug targets. We discovered the formidable anti-inflammatory properties of IL-37 and will now explore how these activites can be utilised in clinical medicine.Read moreRead less
Developing Novel Molecules That Target Hormone Receptors As An Alternative Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$459,867.00
Summary
A promising class of cancer drugs target heat shock protein 90 (Hsp90) and prevent Hsp90 from maintaining its ~100 proteins involved in cell growth. However, all current Hsp90 chemotherapeutics non-selectively target proteins maintained by Hsp90, and induce a cell rescue mechanism involving Hsp70. We describe the development of a novel molecule that will selectively control cell growth and prevent cell rescue via a unique Hsp90 regulated mechanism.